ADCs moving towards brain

Antibody–drug conjugates in brain tumours

Read our June issue to learn more about the activity of ADCs in primary and secondary brain tumours

  • Maximilian J. Mair
  • Rupert Bartsch
  • Matthias Preusser
Review Article


  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic

  • five diverse women

    This regularly updated collection of articles published in the Nature Reviews journals provides in-depth discussions of recent research and medical advances in fields covering women’s health in the broadest sense.


    • The effective management of treatment-related events remains an unmet need in oncology. The authors of this Review discuss the underlying biological mechanisms, risk factors, most commonly used pharmacological and non-pharmacological management strategies, and clinical practice guidelines for the most common long-term (continuing beyond treatment) and late or delayed (following treatment) adverse events associated with chemotherapy and other anticancer treatments.

      • Maryam B. Lustberg
      • Nicole M. Kuderer
      • Gary H. Lyman
      Review Article
    • Dysregulation of N6-methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, is common in various cancer types. The authors of this Review provide an overview of the mechanisms of m6A-dependent RNA regulation, summarize current knowledge of their pathological effects and potential utility as biomarkers in cancer, and describe ongoing efforts to develop small-molecule inhibitors of oncogenic m6A modifiers.

      • Xiaolan Deng
      • Ying Qing
      • Jianjun Chen
      Review Article
    • Cholangiocarcinoma is a malignancy that continues to be associated with a dismal prognosis, and a better understanding of the disease biology is required to improve early detection and treatment strategies. In this Review, the authors describe key scientific and clinical advances made in this area over the past 5 years, encompassing novel insights into the tumour stroma and immune microenvironment, promising progress in developing liquid biopsy approaches for diagnosis and monitoring, clinical translation of molecularly targeted therapies, emerging immunotherapies and reassessment of the potential role of liver transplantation.

      • Sumera I. Ilyas
      • Silvia Affo
      • Gregory J. Gores
      Review Article
    • Bispecific T cell engagers offer a novel treatment approach for patients with multiple myeloma, although mechanisms of resistance are largely unknown. Here, we discuss the implications of a recent report from Friedrich et al. that highlights the importance of pre-treatment T cell characteristics for a response to the T cell engager elranatamab and how these data might be used to inform future study and trial design.

      • Shonali Midha
      • Kenneth C. Anderson
      News & Views
    • Emerging data indicate a central role for the microbiota in all aspects of colorectal cancer (CRC). Despite this general consensus, understanding the role of specific components of the microbiota in such a way that enables the development of clinical interventions or tools to inform clinical decision-making has thus far proved challenging. In this Review, the authors summarize the role of the microbiota in CRC, including in prevention, in interactions with treatment and as a source of novel biomarkers.

      • Chi Chun Wong
      • Jun Yu
      Review Article

Nature Careers